Pharmaceutical Contract Manufacturing Market by Service (Drug Development, Pharmaceutical (API, FDF - Parenteral, Tablet, Capsule), Biologics (API, FDF), Packaging & Labelling, Fill-finish), Molecule (Small, Large (ADC, CGT)) - Global Forecast to 2030
The global pharmaceutical contract manufacturing market is projected to reach USD 311.95 billion by 2030 from an estimated USD 209.90 billion in 2025, at a CAGR of 8.2% from 2025 to 2030. The expansion of the pharmaceutical contract manufacturing market has been predominantly fueled by outsourcing for GLP-1 manufacturing & development, ADC approvals and programs, and loss of exclusivity for blockbuster biologics. However, expansion of in-house capacities by pharmaceutical companies and pricing pressure in the US and Europe are expected to restrict market growth.
The biologics FDF manufacturing services segment reported the highest CAGR in 2024.
Based on biologics manufacturing service, the pharmaceutical contract manufacturing market is segmented into biologics API manufacturing services and biologics FDF Manufacturing Services. Among these, biologics FDF manufacturing services are projected to experience the fastest growth rate during the forecast period from 2025 to 2030. This strong growth outlook is primarily driven by the surging demand for biologics, which include complex and high-value products such as monoclonal antibodies, recombinant proteins, cell and gene therapies, and vaccines. The rising focus on targeted pharmacological therapies, which offer greater efficacy and reduced side effects compared to traditional treatments, is further boosting demand for specialized manufacturing capabilities. In addition, the increasing volume of research and development activities, particularly in cell and gene therapy, contributes significantly to market expansion. A growing number of pipeline candidates in these advanced therapeutic areas requires highly specialized manufacturing processes, encouraging pharmaceutical companies to partner with CDMOs possessing the necessary expertise, infrastructure, and regulatory compliance. This trend is expected to result in higher investment in advanced biologics production technologies, capacity expansion, and quality systems within CDMOs. Consequently, the FDF manufacturing services segment is well-positioned to achieve substantial growth and play an increasingly critical role in the pharmaceutical outsourcing landscape over the coming years.
The small molecules segment dominated the pharmaceutical contract manufacturing market in 2024.
The pharmaceutical contract manufacturing market is segmented by molecules into small molecules & large molecules. In 2024, small molecules, encompassing high-potency small molecules, oligonucleotides and synthetic peptides, radiopharmaceuticals, and other small molecules, hold the largest share of the pharmaceutical CDMO market by molecule segment. High-potency small molecules, particularly oncology, require specialized containment and expertise, driving demand for CDMOs with advanced facilities. Oligonucleotides and synthetic peptides have gained momentum due to their role in precision medicine and targeted therapies, offering new outsourcing opportunities. Radiopharmaceuticals, with applications in diagnostics and treatment, are seeing increased interest as nuclear medicine expands. The other small molecules category remains vital for numerous therapeutic areas, from cardiovascular to infectious diseases. Small molecules are favored for their stability, oral bioavailability, and cost-efficient mass production, making them attractive for both innovative and generic drug pipelines. The growing prevalence of chronic conditions, coupled with ongoing innovation in synthetic chemistry and continuous manufacturing, strengthens their market position. CDMOs with specialized expertise across these subcategories can leverage strong demand from pharmaceutical companies seeking speed, flexibility, and cost efficiency, ensuring that small molecules continue to be a core driver of the CDMO industry’s growth.
North America accounted for the largest share in the global pharmaceutical contract manufacturing market from 2025 to 2030.
North America dominated the pharmaceutical CDMO market in 2024, driven by its strong regulatory framework, advanced manufacturing infrastructure, and high concentration of leading CDMO players. The region benefits from a well-established pharmaceutical industry, extensive R&D capabilities, and a strong presence of big pharmaceutical companies outsourcing development and manufacturing to optimize costs and speed to market. Supportive regulatory agencies, particularly the US FDA, promote innovation through clear guidelines and expedited approvals, encouraging investment in advanced manufacturing technologies such as continuous processing and high-potency API production. North America also leads in biologics and advanced therapies manufacturing, supported by specialized CDMO facilities catering to cell and gene therapies. Strategic collaborations, mergers, and acquisitions further enhance service portfolios and capacity. The region’s robust venture capital ecosystem and academic-industry partnerships foster innovation, while its focus on quality, compliance, and scalability attracts global clients.
The primary interviews conducted for this report can be categorized as follows:
Key players in the pharmaceutical contract manufacturing market include Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), WuXi AppTec (China), WuXi Biologics (China), AbbVie Inc. (US), Catalent, Inc. (Novo Holdings) (US), Samsung Biologics (South Korea), Evonik (Germany), FUJIFILM Holding Corporation (Japan), Siegfried Holding AG (Switzerland), and Boehringer Ingelheim International GmbH (Germany). Other notable companies are Merck KGaA (Germany), Almac Group (UK), Charles River Laboratories (US), Asymchem Inc. (China), Vetter (Germany), and Alcami Corporation (US).
Research Coverage
This research report categorizes the pharmaceutical contract manufacturing market, by service {drug development services, pharmaceutical manufacturing services [pharmaceutical API manufacturing services, pharmaceutical FDF manufacturing services (parenteral, tablet, capsule, oral liquid, semi-solid, other formulations), biologics manufacturing services (biologics API manufacturing services, biologics FDF manufacturing services)], packaging & labelling services, fill-finish services, other services}, molecule [small molecules (high-potency small molecules, oligonucleotide & synthetic peptides, radiopharmaceutical, and other molecules) large molecules (mAbs, CGT, ADC, vaccines, therapeutic peptides & proteins, and other large molecules)], end user (big pharmaceutical companies, small & mid-sized pharmaceutical companies, generic pharmaceutical companies, other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the pharmaceutical contract manufacturing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, acquisitions, and recent developments associated with the pharmaceutical contract manufacturing market.
Reasons to buy this report
The report will help market leaders and new entrants by providing them with closest approximations of the revenue numbers for the overall pharmaceutical contract manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better positioning their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
The biologics FDF manufacturing services segment reported the highest CAGR in 2024.
Based on biologics manufacturing service, the pharmaceutical contract manufacturing market is segmented into biologics API manufacturing services and biologics FDF Manufacturing Services. Among these, biologics FDF manufacturing services are projected to experience the fastest growth rate during the forecast period from 2025 to 2030. This strong growth outlook is primarily driven by the surging demand for biologics, which include complex and high-value products such as monoclonal antibodies, recombinant proteins, cell and gene therapies, and vaccines. The rising focus on targeted pharmacological therapies, which offer greater efficacy and reduced side effects compared to traditional treatments, is further boosting demand for specialized manufacturing capabilities. In addition, the increasing volume of research and development activities, particularly in cell and gene therapy, contributes significantly to market expansion. A growing number of pipeline candidates in these advanced therapeutic areas requires highly specialized manufacturing processes, encouraging pharmaceutical companies to partner with CDMOs possessing the necessary expertise, infrastructure, and regulatory compliance. This trend is expected to result in higher investment in advanced biologics production technologies, capacity expansion, and quality systems within CDMOs. Consequently, the FDF manufacturing services segment is well-positioned to achieve substantial growth and play an increasingly critical role in the pharmaceutical outsourcing landscape over the coming years.
The small molecules segment dominated the pharmaceutical contract manufacturing market in 2024.
The pharmaceutical contract manufacturing market is segmented by molecules into small molecules & large molecules. In 2024, small molecules, encompassing high-potency small molecules, oligonucleotides and synthetic peptides, radiopharmaceuticals, and other small molecules, hold the largest share of the pharmaceutical CDMO market by molecule segment. High-potency small molecules, particularly oncology, require specialized containment and expertise, driving demand for CDMOs with advanced facilities. Oligonucleotides and synthetic peptides have gained momentum due to their role in precision medicine and targeted therapies, offering new outsourcing opportunities. Radiopharmaceuticals, with applications in diagnostics and treatment, are seeing increased interest as nuclear medicine expands. The other small molecules category remains vital for numerous therapeutic areas, from cardiovascular to infectious diseases. Small molecules are favored for their stability, oral bioavailability, and cost-efficient mass production, making them attractive for both innovative and generic drug pipelines. The growing prevalence of chronic conditions, coupled with ongoing innovation in synthetic chemistry and continuous manufacturing, strengthens their market position. CDMOs with specialized expertise across these subcategories can leverage strong demand from pharmaceutical companies seeking speed, flexibility, and cost efficiency, ensuring that small molecules continue to be a core driver of the CDMO industry’s growth.
North America accounted for the largest share in the global pharmaceutical contract manufacturing market from 2025 to 2030.
North America dominated the pharmaceutical CDMO market in 2024, driven by its strong regulatory framework, advanced manufacturing infrastructure, and high concentration of leading CDMO players. The region benefits from a well-established pharmaceutical industry, extensive R&D capabilities, and a strong presence of big pharmaceutical companies outsourcing development and manufacturing to optimize costs and speed to market. Supportive regulatory agencies, particularly the US FDA, promote innovation through clear guidelines and expedited approvals, encouraging investment in advanced manufacturing technologies such as continuous processing and high-potency API production. North America also leads in biologics and advanced therapies manufacturing, supported by specialized CDMO facilities catering to cell and gene therapies. Strategic collaborations, mergers, and acquisitions further enhance service portfolios and capacity. The region’s robust venture capital ecosystem and academic-industry partnerships foster innovation, while its focus on quality, compliance, and scalability attracts global clients.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side- 30%
- By Designation: Managers- 45%, CXO and Directors- 30%, and Executives- 25%
- By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5%
Key players in the pharmaceutical contract manufacturing market include Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), WuXi AppTec (China), WuXi Biologics (China), AbbVie Inc. (US), Catalent, Inc. (Novo Holdings) (US), Samsung Biologics (South Korea), Evonik (Germany), FUJIFILM Holding Corporation (Japan), Siegfried Holding AG (Switzerland), and Boehringer Ingelheim International GmbH (Germany). Other notable companies are Merck KGaA (Germany), Almac Group (UK), Charles River Laboratories (US), Asymchem Inc. (China), Vetter (Germany), and Alcami Corporation (US).
Research Coverage
This research report categorizes the pharmaceutical contract manufacturing market, by service {drug development services, pharmaceutical manufacturing services [pharmaceutical API manufacturing services, pharmaceutical FDF manufacturing services (parenteral, tablet, capsule, oral liquid, semi-solid, other formulations), biologics manufacturing services (biologics API manufacturing services, biologics FDF manufacturing services)], packaging & labelling services, fill-finish services, other services}, molecule [small molecules (high-potency small molecules, oligonucleotide & synthetic peptides, radiopharmaceutical, and other molecules) large molecules (mAbs, CGT, ADC, vaccines, therapeutic peptides & proteins, and other large molecules)], end user (big pharmaceutical companies, small & mid-sized pharmaceutical companies, generic pharmaceutical companies, other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the pharmaceutical contract manufacturing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, acquisitions, and recent developments associated with the pharmaceutical contract manufacturing market.
Reasons to buy this report
The report will help market leaders and new entrants by providing them with closest approximations of the revenue numbers for the overall pharmaceutical contract manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better positioning their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (GLP-1 capacity crunch, increasing development and manufacturing of antibody drug conjugates, loss of exclusivity of blockbuster biologics, increasing complexity of injectable drug formats) restraints (pricing pressure on innovator drugs, growing penetration of generics and biosimilars, strict regulatory compliance, risk in advanced therapies pipeline), opportunities (Rising demand for cell and gene therapies, growing inclination toward one-stop-shop model, market expansion in emerging countries, booming radiopharmaceutical and nuclear medicine segment), and challenges (global trade instability and insourcing) influencing the growth of pharmaceutical contract development and manufacturing market.
- Service Development/Innovation: Thorough investigation of recently launched services available in the pharmaceutical contract manufacturing market.
- Market Development: Utilizing analysis of regional market trends, the study offers comprehensive knowledge on profitable markets.
- Market Diversification: Comprehensive information on new services, underdeveloped areas, present developments, and pharmaceutical contract manufacturing sector investments is what market diversification is based on.
- Competitive Assessment: A comprehensive evaluation of the market shares, growth strategies, and service offerings of prominent companies such as Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza (Switzerland), AbbVie Inc. (US), WuXi AppTec (China), and others in the pharmaceutical contract development and manufacturing market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key objectives of secondary research
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 Company revenue analysis (Bottom-up approach)
2.2.1.2 MnM repository analysis
2.2.1.3 Primary interviews
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
3.1.1 PHARMACEUTICAL CONTRACT MANUFACTURERS
3.1.1.1 Capacity lock in for GLP-1 and biologics opportunities
3.1.1.2 Sterile fill-finish services
3.1.1.3 OSD differentiation and dual site sourcing
3.1.2 PHARMACEUTICAL COMPANIES
3.1.2.1 Own vs. outsourcing critical steps
3.1.2.2 Dual-source, multi-site supply resilience
3.1.3 STARTUPS AND INNOVATIVE BIOTECH FIRMS
3.1.3.1 Gene-to-IND platform
3.1.3.2 Clinical supply risk management
4 PREMIUM INSIGHTS
4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW
4.2 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE AND COUNTRY, 2025
4.3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE
4.4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
4.5 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EMERGING VS. DEVELOPED MARKETS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 GLP-1 capacity crunch
5.2.1.2 Increasing development and manufacturing of antibody drug conjugates
5.2.1.3 Loss of exclusivity of blockbuster biologics
5.2.1.4 Increasing complexity of injectable drug formats
5.2.2 RESTRAINTS
5.2.2.1 Pricing pressure on innovator drugs
5.2.2.2 Growing penetration of generics and biosimilars
5.2.2.3 Strict regulatory compliance
5.2.2.4 Risk in advanced therapies pipeline
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for cell and gene therapies
5.2.3.2 Growing inclination toward one-stop-shop model
5.2.3.3 Market expansion in emerging countries
5.2.3.4 Booming radiopharmaceutical and nuclear medicine segment
5.2.4 CHALLENGES
5.2.4.1 Global trade instability and insourcing
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 INDICATIVE PRICING ANALYSIS, BY SERVICE
5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION
5.4.3 COMPARISON OF CDMO PRICING MODELS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.7.1 MANUFACTURING SITE, EXPANSION, AND CAPEX TREND OF KEY CDMOS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Single-use bioprocessing systems
5.9.1.2 Continuous manufacturing
5.9.1.3 Advanced formulation technologies
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 High-performance liquid chromatography
5.9.2.2 Mass spectrometry
5.9.2.3 Next-generation sequencing
5.9.2.4 Automation and robotics
5.9.2.5 Process analytical technology
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 3D printing
5.9.3.2 Artificial intelligence and machine learning
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES AND EVENTS, 2025–2026
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY SCENARIO
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 BARGAINING POWER OF SUPPLIERS
5.13.2 BARGAINING POWER OF BUYERS
5.13.3 THREAT OF NEW ENTRANTS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 UNMET NEEDS OF END USERS
5.15.1 CAPACITY AND TIMELY ACCESS
5.15.2 COST EFFICIENCY AND FLEXIBILITY
5.15.3 END-TO-END INTEGRATED SERVICES
5.15.4 ADVANCED MODALITY EXPERTISE
5.15.5 QUALITY AND REGULATORY CONSISTENCY
5.16 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS
5.17 IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
5.17.1 INTRODUCTION
5.17.2 MARKET POTENTIAL OF AI/GEN AI
5.17.3 AI USE CASES
5.17.4 KEY COMPANIES IMPLEMENTING AI/GEN AI
5.18 IMPACT OF 2025 US TARIFFS ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 IMPACT ON COUNTRY/REGION
5.18.4.1 US
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.4.3.1 India
5.18.5 IMPACT ON END-USE INDUSTRIES
6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE
6.1 INTRODUCTION
6.2 PHARMACEUTICAL MANUFACTURING SERVICES
6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
6.2.1.1 Rising cases of patent expiry to fuel market
6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
6.2.2.1 Parenteral manufacturing services
6.2.2.1.1 Increasing demand for specialized manufacturing capabilities to support growth
6.2.2.2 Tablet manufacturing services
6.2.2.2.1 Growing domestic production capacity in emerging markets to boost market
6.2.2.3 Capsule manufacturing services
6.2.2.3.1 Rising adoption in pharmaceutical, nutraceutical, and cosmetic applications to stimulate growth
6.2.2.4 Oral liquid manufacturing services
6.2.2.4.1 Growing preference for oral liquids over powders to fuel market
6.2.2.5 Semi-solid manufacturing services
6.2.2.5.1 Rising prevalence of skin infections and burns to foster growth
6.2.2.6 Other FDF manufacturing services
6.3 DRUG DEVELOPMENT SERVICES
6.3.1 INCREASING COST OF DRUG DISCOVERY AND DEVELOPMENT TO EXPEDITE GROWTH
6.4 BIOLOGICS MANUFACTURING SERVICES
6.4.1 BIOLOGICS API MANUFACTURING SERVICES
6.4.1.1 Rising investments in single-use production capacities to bolster growth
6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
6.4.2.1 Growing demand for generic medicines and biologics to fuel market
6.5 PACKAGING & LABELING SERVICES
6.5.1 INCREASING COMPLEXITY AND STRINGENCY OF REGULATORY REQUIREMENTS FOR DRUG SAFETY AND EFFICACY TO FAVOR GROWTH
6.6 FILL-FINISH SERVICES
6.6.1 SURGE IN DEMAND FOR BIOLOGICS AND COMPLEX INJECTABLE THERAPIES TO BOOST MARKET
6.7 OTHER SERVICES
7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE
7.1 INTRODUCTION
7.2 SMALL MOLECULES
7.2.1 HIGH-POTENCY SMALL MOLECULES
7.2.1.1 Increasing adoption of high-potency small molecules for treating oncology, rare diseases, and other diseases to aid growth
7.2.2 OLIGONUCLEOTIDE & SYNTHETIC PEPTIDES
7.2.2.1 Growing focus on next-gen therapies to drive market
7.2.3 RADIOPHARMACEUTICAL MOLECULES
7.2.3.1 Advances in isotope production, radiolabeling chemistry, and theranostic approaches to boost market
7.2.4 OTHER SMALL MOLECULES
7.3 LARGE MOLECULES
7.3.1 MONOCLONAL ANTIBODIES
7.3.1.1 Rising use of mAbs in managing cancer, autoimmune disorders, and osteoporosis to spur growth
7.3.2 CELL & GENE THERAPIES
7.3.2.1 Emerging treatments for previously untreatable genetic and rare diseases to boost market
7.3.3 ANTIBODY DRUG CONJUGATES
7.3.3.1 Growing need for precision medicines to fuel market
7.3.4 VACCINES
7.3.4.1 Growing threat of infectious disease outbreaks to drive market
7.3.5 THERAPEUTIC PEPTIDES & PROTEINS
7.3.5.1 Increasing research in genomics to support growth
7.3.6 OTHER LARGE MOLECULES
8 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
8.1 INTRODUCTION
8.2 BIG PHARMACEUTICAL COMPANIES
8.2.1 PRICING PRESSURE IN PHARMACEUTICAL INDUSTRY TO CONTRIBUTE TO GROWTH
8.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
8.3.1 NEED TO SAVE IN-HOUSE DRUG MANUFACTURING COST TO FOSTER GROWTH
8.4 GENERIC PHARMACEUTICAL COMPANIES
8.4.1 FAVORABLE GOVERNMENT SUPPORT FOR ADOPTION OF GENERIC DRUGS TO PROPEL MARKET
8.5 OTHER END USERS
9 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 High clinical trial and drug discovery activities to foster growth
9.2.3 CANADA
9.2.3.1 Favorable government support and increased focus on R&D activities to sustain growth
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 Free drug-pricing policy and high pharmaceutical investments to speed up growth
9.3.3 UK
9.3.3.1 Favorable R&D funding scenario to augment growth
9.3.4 FRANCE
9.3.4.1 Booming life science research and growing generics market to drive market
9.3.5 ITALY
9.3.5.1 Rising commercial drug development and increasing life science R&D to favor growth
9.3.6 SWITZERLAND
9.3.6.1 Rapid growth as global pharmaceutical manufacturing hub to drive market
9.3.7 POLAND
9.3.7.1 Universal health coverage and advanced government-supported medical infrastructure to encourage growth
9.3.8 SPAIN
9.3.8.1 Growing pharmaceutical R&D expenditure and increasing outsourcing of trial phases to boost market
9.3.9 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 Made in China 2025 initiative and high government drug development investments to aid growth
9.4.3 JAPAN
9.4.3.1 High geriatric population and advanced pharmaceutical research to augment growth
9.4.4 SOUTH KOREA
9.4.4.1 Increased biotech investments and developed pharma sector to propel market
9.4.5 INDIA
9.4.5.1 Favorable industrial environment and lower labor costs to drive market
9.4.6 AUSTRALIA
9.4.6.1 Strategic geographical location and stringent regulatory environment to foster growth
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Rapid patient enrolment and increased focus on advanced clinical trials to expedite growth
9.5.3 MEXICO
9.5.3.1 Surge in pharmaceutical goods export to promote growth
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
9.6.2 GCC COUNTRIES
9.6.2.1 Kingdom of Saudi Arabia (KSA)
9.6.2.1.1 Increasing healthcare expenditure to aid growth
9.6.2.2 UAE
9.6.2.2.1 Strategic government healthcare initiatives and broader economic diversification plans to drive market
9.6.2.3 Rest of GCC countries
9.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 RISING PREVALENCE OF CHRONIC DISEASES TO FACILITATE GROWTH
9.7.2 MACROECONOMIC OUTLOOK OF AFRICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.3 REVENUE SHARE ANALYSIS, 2020–2024
10.4 MARKET SHARE ANALYSIS, 2024
10.5 COMPANY VALUATION AND FINANCIAL METRICS
10.6 BRAND/SERVICE COMPARISON
10.6.1 THERMO FISHER SCIENTIFIC INC.
10.6.2 LONZA
10.6.3 WUXI BIOLOGICS AND WUXI APPTEC
10.6.4 CATALENT, INC.
10.6.5 SAMSUNG BIOLOGICS
10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.7.1 STARS
10.7.2 EMERGING LEADERS
10.7.3 PERVASIVE PLAYERS
10.7.4 PARTICIPANTS
10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
10.7.5.1 Company footprint
10.7.5.2 Region footprint
10.7.5.3 Service footprint
10.7.5.4 Molecule footprint
10.8 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
10.8.1 PROGRESSIVE COMPANIES
10.8.2 RESPONSIVE COMPANIES
10.8.3 DYNAMIC COMPANIES
10.8.4 STARTING BLOCKS
10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.8.5.1 Detailed list of key startups/SMEs
10.8.5.2 Competitive benchmarking of key startups/SMEs
10.9 COMPETITIVE SCENARIO
10.9.1 SERVICE LAUNCHES
10.9.2 DEALS
10.9.3 EXPANSIONS
11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 THERMO FISHER SCIENTIFIC INC.
11.1.1.1 Business overview
11.1.1.2 Services offered
11.1.1.3 Recent developments
11.1.1.3.1 Service launches
11.1.1.3.2 Deals
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses and competitive threats
11.1.2 LONZA
11.1.2.1 Business overview
11.1.2.2 Services offered
11.1.2.3 Recent developments
11.1.2.3.1 Deals
11.1.2.3.2 Expansions
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses and competitive threats
11.1.3 CATALENT, INC.
11.1.3.1 Business overview
11.1.3.2 Services offered
11.1.3.3 Recent developments
11.1.3.3.1 Service launches
11.1.3.3.2 Deals
11.1.3.3.3 Expansions
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses and competitive threats
11.1.4 WUXI APPTEC
11.1.4.1 Business overview
11.1.4.2 Services offered
11.1.4.3 Recent developments
11.1.4.3.1 Deals
11.1.4.3.2 Expansions
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses and competitive threats
11.1.5 WUXI BIOLOGICS
11.1.5.1 Business overview
11.1.5.2 Services offered
11.1.5.3 Recent developments
11.1.5.3.1 Service launches
11.1.5.3.2 Deals
11.1.5.3.3 Expansions
11.1.5.3.4 Other developments
11.1.6 SAMSUNG BIOLOGICS
11.1.6.1 Business overview
11.1.6.2 Services offered
11.1.6.3 Recent developments
11.1.6.3.1 Service launches
11.1.6.3.2 Deals
11.1.6.3.3 Expansions
11.1.7 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
11.1.7.1 Business overview
11.1.7.2 Services offered
11.1.7.3 Recent developments
11.1.7.3.1 Deals
11.1.7.3.2 Expansions
11.1.7.3.3 Other developments
11.1.8 EVONIK
11.1.8.1 Business overview
11.1.8.2 Services offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.8.3.2 Expansions
11.1.9 FUJIFILM HOLDINGS CORPORATION
11.1.9.1 Business overview
11.1.9.2 Services offered
11.1.9.3 Recent developments
11.1.9.3.1 Deals
11.1.9.3.2 Expansions
11.1.10 ABBVIE INC.
11.1.10.1 Business overview
11.1.10.2 Services offered
11.1.10.3 Recent developments
11.1.10.3.1 Deals
11.1.10.3.2 Expansions
11.1.11 SIEGFRIED HOLDING AG
11.1.11.1 Business overview
11.1.11.2 Services offered
11.1.11.3 Recent developments
11.1.11.3.1 Deals
11.1.11.3.2 Expansions
11.1.12 MERCK KGAA
11.1.12.1 Business overview
11.1.12.2 Services offered
11.1.12.3 Recent developments
11.1.12.3.1 Deals
11.1.12.3.2 Expansions
11.1.13 ALMAC GROUP
11.1.13.1 Business overview
11.1.13.2 Services offered
11.1.13.3 Recent developments
11.1.13.3.1 Deals
11.1.13.3.2 Expansions
11.1.14 CHARLES RIVER LABORATORIES
11.1.14.1 Business overview
11.1.14.2 Services offered
11.1.14.3 Recent developments
11.1.14.3.1 Deals
11.1.14.3.2 Expansions
11.1.15 ASYMCHEM INC.
11.1.15.1 Business overview
11.1.15.2 Services offered
11.1.15.3 Recent developments
11.1.15.3.1 Deals
11.1.15.3.2 Expansions
11.1.16 VETTER
11.1.16.1 Business overview
11.1.16.2 Services offered
11.1.16.3 Recent developments
11.1.16.3.1 Service launches
11.1.16.3.2 Deals
11.1.16.3.3 Expansions
11.1.17 ALCAMI CORPORATION
11.1.17.1 Business overview
11.1.17.2 Services offered
11.1.17.3 Recent developments
11.1.17.3.1 Deals
11.1.17.3.2 Expansions
11.1.18 EUROFINS SCIENTIFIC
11.1.18.1 Business overview
11.1.18.2 Services offered
11.1.18.3 Recent developments
11.1.18.3.1 Expansions
11.2 OTHER PLAYERS
11.2.1 PIRAMAL PHARMA SOLUTIONS
11.2.2 SYNGENE INTERNATIONAL LIMITED
11.2.3 CAMBREX CORPORATION
11.2.4 JUBILANT PHARMANOVA LIMITED
11.2.5 YUHAN CORPORATION
11.2.6 PIERRE FABRE LABORATORIES
11.2.7 PFIZER CENTREONE
11.2.8 DELPHARM
11.2.9 FRONTAGE LABS
11.2.10 SHARP SERVICES, LLC
11.2.11 GRAND RIVER ASEPTIC MANUFACTURING
11.2.12 RECIPHARM AB
11.2.13 PCI PHARMA SERVICES
11.2.14 CURIA GLOBAL, INC.
11.2.15 SIMTRA BIOPHARMA SOLUTIONS
11.2.16 PORTON
11.2.17 MABPLEX INTERNATIONAL CO. LTD.
11.2.18 CELLARES
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key objectives of secondary research
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.1.1 Company revenue analysis (Bottom-up approach)
2.2.1.2 MnM repository analysis
2.2.1.3 Primary interviews
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
3.1.1 PHARMACEUTICAL CONTRACT MANUFACTURERS
3.1.1.1 Capacity lock in for GLP-1 and biologics opportunities
3.1.1.2 Sterile fill-finish services
3.1.1.3 OSD differentiation and dual site sourcing
3.1.2 PHARMACEUTICAL COMPANIES
3.1.2.1 Own vs. outsourcing critical steps
3.1.2.2 Dual-source, multi-site supply resilience
3.1.3 STARTUPS AND INNOVATIVE BIOTECH FIRMS
3.1.3.1 Gene-to-IND platform
3.1.3.2 Clinical supply risk management
4 PREMIUM INSIGHTS
4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW
4.2 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE AND COUNTRY, 2025
4.3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE
4.4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
4.5 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EMERGING VS. DEVELOPED MARKETS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 GLP-1 capacity crunch
5.2.1.2 Increasing development and manufacturing of antibody drug conjugates
5.2.1.3 Loss of exclusivity of blockbuster biologics
5.2.1.4 Increasing complexity of injectable drug formats
5.2.2 RESTRAINTS
5.2.2.1 Pricing pressure on innovator drugs
5.2.2.2 Growing penetration of generics and biosimilars
5.2.2.3 Strict regulatory compliance
5.2.2.4 Risk in advanced therapies pipeline
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for cell and gene therapies
5.2.3.2 Growing inclination toward one-stop-shop model
5.2.3.3 Market expansion in emerging countries
5.2.3.4 Booming radiopharmaceutical and nuclear medicine segment
5.2.4 CHALLENGES
5.2.4.1 Global trade instability and insourcing
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 INDICATIVE PRICING ANALYSIS, BY SERVICE
5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION
5.4.3 COMPARISON OF CDMO PRICING MODELS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.7.1 MANUFACTURING SITE, EXPANSION, AND CAPEX TREND OF KEY CDMOS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Single-use bioprocessing systems
5.9.1.2 Continuous manufacturing
5.9.1.3 Advanced formulation technologies
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 High-performance liquid chromatography
5.9.2.2 Mass spectrometry
5.9.2.3 Next-generation sequencing
5.9.2.4 Automation and robotics
5.9.2.5 Process analytical technology
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 3D printing
5.9.3.2 Artificial intelligence and machine learning
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES AND EVENTS, 2025–2026
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY SCENARIO
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 BARGAINING POWER OF SUPPLIERS
5.13.2 BARGAINING POWER OF BUYERS
5.13.3 THREAT OF NEW ENTRANTS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 UNMET NEEDS OF END USERS
5.15.1 CAPACITY AND TIMELY ACCESS
5.15.2 COST EFFICIENCY AND FLEXIBILITY
5.15.3 END-TO-END INTEGRATED SERVICES
5.15.4 ADVANCED MODALITY EXPERTISE
5.15.5 QUALITY AND REGULATORY CONSISTENCY
5.16 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS
5.17 IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
5.17.1 INTRODUCTION
5.17.2 MARKET POTENTIAL OF AI/GEN AI
5.17.3 AI USE CASES
5.17.4 KEY COMPANIES IMPLEMENTING AI/GEN AI
5.18 IMPACT OF 2025 US TARIFFS ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 IMPACT ON COUNTRY/REGION
5.18.4.1 US
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.4.3.1 India
5.18.5 IMPACT ON END-USE INDUSTRIES
6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE
6.1 INTRODUCTION
6.2 PHARMACEUTICAL MANUFACTURING SERVICES
6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
6.2.1.1 Rising cases of patent expiry to fuel market
6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
6.2.2.1 Parenteral manufacturing services
6.2.2.1.1 Increasing demand for specialized manufacturing capabilities to support growth
6.2.2.2 Tablet manufacturing services
6.2.2.2.1 Growing domestic production capacity in emerging markets to boost market
6.2.2.3 Capsule manufacturing services
6.2.2.3.1 Rising adoption in pharmaceutical, nutraceutical, and cosmetic applications to stimulate growth
6.2.2.4 Oral liquid manufacturing services
6.2.2.4.1 Growing preference for oral liquids over powders to fuel market
6.2.2.5 Semi-solid manufacturing services
6.2.2.5.1 Rising prevalence of skin infections and burns to foster growth
6.2.2.6 Other FDF manufacturing services
6.3 DRUG DEVELOPMENT SERVICES
6.3.1 INCREASING COST OF DRUG DISCOVERY AND DEVELOPMENT TO EXPEDITE GROWTH
6.4 BIOLOGICS MANUFACTURING SERVICES
6.4.1 BIOLOGICS API MANUFACTURING SERVICES
6.4.1.1 Rising investments in single-use production capacities to bolster growth
6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
6.4.2.1 Growing demand for generic medicines and biologics to fuel market
6.5 PACKAGING & LABELING SERVICES
6.5.1 INCREASING COMPLEXITY AND STRINGENCY OF REGULATORY REQUIREMENTS FOR DRUG SAFETY AND EFFICACY TO FAVOR GROWTH
6.6 FILL-FINISH SERVICES
6.6.1 SURGE IN DEMAND FOR BIOLOGICS AND COMPLEX INJECTABLE THERAPIES TO BOOST MARKET
6.7 OTHER SERVICES
7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE
7.1 INTRODUCTION
7.2 SMALL MOLECULES
7.2.1 HIGH-POTENCY SMALL MOLECULES
7.2.1.1 Increasing adoption of high-potency small molecules for treating oncology, rare diseases, and other diseases to aid growth
7.2.2 OLIGONUCLEOTIDE & SYNTHETIC PEPTIDES
7.2.2.1 Growing focus on next-gen therapies to drive market
7.2.3 RADIOPHARMACEUTICAL MOLECULES
7.2.3.1 Advances in isotope production, radiolabeling chemistry, and theranostic approaches to boost market
7.2.4 OTHER SMALL MOLECULES
7.3 LARGE MOLECULES
7.3.1 MONOCLONAL ANTIBODIES
7.3.1.1 Rising use of mAbs in managing cancer, autoimmune disorders, and osteoporosis to spur growth
7.3.2 CELL & GENE THERAPIES
7.3.2.1 Emerging treatments for previously untreatable genetic and rare diseases to boost market
7.3.3 ANTIBODY DRUG CONJUGATES
7.3.3.1 Growing need for precision medicines to fuel market
7.3.4 VACCINES
7.3.4.1 Growing threat of infectious disease outbreaks to drive market
7.3.5 THERAPEUTIC PEPTIDES & PROTEINS
7.3.5.1 Increasing research in genomics to support growth
7.3.6 OTHER LARGE MOLECULES
8 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
8.1 INTRODUCTION
8.2 BIG PHARMACEUTICAL COMPANIES
8.2.1 PRICING PRESSURE IN PHARMACEUTICAL INDUSTRY TO CONTRIBUTE TO GROWTH
8.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
8.3.1 NEED TO SAVE IN-HOUSE DRUG MANUFACTURING COST TO FOSTER GROWTH
8.4 GENERIC PHARMACEUTICAL COMPANIES
8.4.1 FAVORABLE GOVERNMENT SUPPORT FOR ADOPTION OF GENERIC DRUGS TO PROPEL MARKET
8.5 OTHER END USERS
9 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 High clinical trial and drug discovery activities to foster growth
9.2.3 CANADA
9.2.3.1 Favorable government support and increased focus on R&D activities to sustain growth
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.2.1 Free drug-pricing policy and high pharmaceutical investments to speed up growth
9.3.3 UK
9.3.3.1 Favorable R&D funding scenario to augment growth
9.3.4 FRANCE
9.3.4.1 Booming life science research and growing generics market to drive market
9.3.5 ITALY
9.3.5.1 Rising commercial drug development and increasing life science R&D to favor growth
9.3.6 SWITZERLAND
9.3.6.1 Rapid growth as global pharmaceutical manufacturing hub to drive market
9.3.7 POLAND
9.3.7.1 Universal health coverage and advanced government-supported medical infrastructure to encourage growth
9.3.8 SPAIN
9.3.8.1 Growing pharmaceutical R&D expenditure and increasing outsourcing of trial phases to boost market
9.3.9 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 Made in China 2025 initiative and high government drug development investments to aid growth
9.4.3 JAPAN
9.4.3.1 High geriatric population and advanced pharmaceutical research to augment growth
9.4.4 SOUTH KOREA
9.4.4.1 Increased biotech investments and developed pharma sector to propel market
9.4.5 INDIA
9.4.5.1 Favorable industrial environment and lower labor costs to drive market
9.4.6 AUSTRALIA
9.4.6.1 Strategic geographical location and stringent regulatory environment to foster growth
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Rapid patient enrolment and increased focus on advanced clinical trials to expedite growth
9.5.3 MEXICO
9.5.3.1 Surge in pharmaceutical goods export to promote growth
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
9.6.2 GCC COUNTRIES
9.6.2.1 Kingdom of Saudi Arabia (KSA)
9.6.2.1.1 Increasing healthcare expenditure to aid growth
9.6.2.2 UAE
9.6.2.2.1 Strategic government healthcare initiatives and broader economic diversification plans to drive market
9.6.2.3 Rest of GCC countries
9.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 RISING PREVALENCE OF CHRONIC DISEASES TO FACILITATE GROWTH
9.7.2 MACROECONOMIC OUTLOOK OF AFRICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.3 REVENUE SHARE ANALYSIS, 2020–2024
10.4 MARKET SHARE ANALYSIS, 2024
10.5 COMPANY VALUATION AND FINANCIAL METRICS
10.6 BRAND/SERVICE COMPARISON
10.6.1 THERMO FISHER SCIENTIFIC INC.
10.6.2 LONZA
10.6.3 WUXI BIOLOGICS AND WUXI APPTEC
10.6.4 CATALENT, INC.
10.6.5 SAMSUNG BIOLOGICS
10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.7.1 STARS
10.7.2 EMERGING LEADERS
10.7.3 PERVASIVE PLAYERS
10.7.4 PARTICIPANTS
10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
10.7.5.1 Company footprint
10.7.5.2 Region footprint
10.7.5.3 Service footprint
10.7.5.4 Molecule footprint
10.8 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
10.8.1 PROGRESSIVE COMPANIES
10.8.2 RESPONSIVE COMPANIES
10.8.3 DYNAMIC COMPANIES
10.8.4 STARTING BLOCKS
10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.8.5.1 Detailed list of key startups/SMEs
10.8.5.2 Competitive benchmarking of key startups/SMEs
10.9 COMPETITIVE SCENARIO
10.9.1 SERVICE LAUNCHES
10.9.2 DEALS
10.9.3 EXPANSIONS
11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 THERMO FISHER SCIENTIFIC INC.
11.1.1.1 Business overview
11.1.1.2 Services offered
11.1.1.3 Recent developments
11.1.1.3.1 Service launches
11.1.1.3.2 Deals
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses and competitive threats
11.1.2 LONZA
11.1.2.1 Business overview
11.1.2.2 Services offered
11.1.2.3 Recent developments
11.1.2.3.1 Deals
11.1.2.3.2 Expansions
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses and competitive threats
11.1.3 CATALENT, INC.
11.1.3.1 Business overview
11.1.3.2 Services offered
11.1.3.3 Recent developments
11.1.3.3.1 Service launches
11.1.3.3.2 Deals
11.1.3.3.3 Expansions
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses and competitive threats
11.1.4 WUXI APPTEC
11.1.4.1 Business overview
11.1.4.2 Services offered
11.1.4.3 Recent developments
11.1.4.3.1 Deals
11.1.4.3.2 Expansions
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses and competitive threats
11.1.5 WUXI BIOLOGICS
11.1.5.1 Business overview
11.1.5.2 Services offered
11.1.5.3 Recent developments
11.1.5.3.1 Service launches
11.1.5.3.2 Deals
11.1.5.3.3 Expansions
11.1.5.3.4 Other developments
11.1.6 SAMSUNG BIOLOGICS
11.1.6.1 Business overview
11.1.6.2 Services offered
11.1.6.3 Recent developments
11.1.6.3.1 Service launches
11.1.6.3.2 Deals
11.1.6.3.3 Expansions
11.1.7 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
11.1.7.1 Business overview
11.1.7.2 Services offered
11.1.7.3 Recent developments
11.1.7.3.1 Deals
11.1.7.3.2 Expansions
11.1.7.3.3 Other developments
11.1.8 EVONIK
11.1.8.1 Business overview
11.1.8.2 Services offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.8.3.2 Expansions
11.1.9 FUJIFILM HOLDINGS CORPORATION
11.1.9.1 Business overview
11.1.9.2 Services offered
11.1.9.3 Recent developments
11.1.9.3.1 Deals
11.1.9.3.2 Expansions
11.1.10 ABBVIE INC.
11.1.10.1 Business overview
11.1.10.2 Services offered
11.1.10.3 Recent developments
11.1.10.3.1 Deals
11.1.10.3.2 Expansions
11.1.11 SIEGFRIED HOLDING AG
11.1.11.1 Business overview
11.1.11.2 Services offered
11.1.11.3 Recent developments
11.1.11.3.1 Deals
11.1.11.3.2 Expansions
11.1.12 MERCK KGAA
11.1.12.1 Business overview
11.1.12.2 Services offered
11.1.12.3 Recent developments
11.1.12.3.1 Deals
11.1.12.3.2 Expansions
11.1.13 ALMAC GROUP
11.1.13.1 Business overview
11.1.13.2 Services offered
11.1.13.3 Recent developments
11.1.13.3.1 Deals
11.1.13.3.2 Expansions
11.1.14 CHARLES RIVER LABORATORIES
11.1.14.1 Business overview
11.1.14.2 Services offered
11.1.14.3 Recent developments
11.1.14.3.1 Deals
11.1.14.3.2 Expansions
11.1.15 ASYMCHEM INC.
11.1.15.1 Business overview
11.1.15.2 Services offered
11.1.15.3 Recent developments
11.1.15.3.1 Deals
11.1.15.3.2 Expansions
11.1.16 VETTER
11.1.16.1 Business overview
11.1.16.2 Services offered
11.1.16.3 Recent developments
11.1.16.3.1 Service launches
11.1.16.3.2 Deals
11.1.16.3.3 Expansions
11.1.17 ALCAMI CORPORATION
11.1.17.1 Business overview
11.1.17.2 Services offered
11.1.17.3 Recent developments
11.1.17.3.1 Deals
11.1.17.3.2 Expansions
11.1.18 EUROFINS SCIENTIFIC
11.1.18.1 Business overview
11.1.18.2 Services offered
11.1.18.3 Recent developments
11.1.18.3.1 Expansions
11.2 OTHER PLAYERS
11.2.1 PIRAMAL PHARMA SOLUTIONS
11.2.2 SYNGENE INTERNATIONAL LIMITED
11.2.3 CAMBREX CORPORATION
11.2.4 JUBILANT PHARMANOVA LIMITED
11.2.5 YUHAN CORPORATION
11.2.6 PIERRE FABRE LABORATORIES
11.2.7 PFIZER CENTREONE
11.2.8 DELPHARM
11.2.9 FRONTAGE LABS
11.2.10 SHARP SERVICES, LLC
11.2.11 GRAND RIVER ASEPTIC MANUFACTURING
11.2.12 RECIPHARM AB
11.2.13 PCI PHARMA SERVICES
11.2.14 CURIA GLOBAL, INC.
11.2.15 SIMTRA BIOPHARMA SOLUTIONS
11.2.16 PORTON
11.2.17 MABPLEX INTERNATIONAL CO. LTD.
11.2.18 CELLARES
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RISK ANALYSIS
TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 5 GLP-1 PIPELINE, EXPECTED LAUNCH BY 2030
TABLE 6 ADC PIPELINE, EXPECTED LAUNCH BY 2030
TABLE 7 IMPENDING AND ONGOING PATENT EXPIRIES OF BLOCKBUSTER BIOLOGICS, 2023–2035
TABLE 8 LIST OF RECENTLY APPROVED INJECTABLES, 2022–2024
TABLE 9 CELL & GENE THERAPY-SPECIFIC CDMO EXPANSIONS, 2023–2025
TABLE 10 CELL & GENE THERAPY PIPELINE, EXPECTED LAUNCH BY 2030
TABLE 11 INDICATIVE PRICING ANALYSIS, BY SERVICE
TABLE 12 INDICATIVE PRICING ANALYSIS, BY REGION
TABLE 13 PRICING MODELS FOR CDMO SERVICES
TABLE 14 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN SUPPLY CHAIN
TABLE 15 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 16 MANUFACTURING SITES OF KEY CDMOS
TABLE 17 LIST OF SITE EXPANSIONS FOR KEY CDMOS, 2023–2025
TABLE 18 CAPEX FOR SELECTED PUBLICLY LISTED KEY CDMOS, 2021–2024 (USD MILLION)
TABLE 19 NUMBER OF PATENTS FILED IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2014–2024
TABLE 20 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
TABLE 21 REGULATORY SCENARIO, BY COUNTRY
TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 27 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 28 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PHARMACEUTICAL CONTRACT MANUFACTURING SERVICES (%)
TABLE 30 BUYING CRITERIA FOR PHARMACEUTICAL CONTRACT MANUFACTURING,BY END USER
TABLE 31 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 32 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE,2023–2030 (USD BILLION)
TABLE 33 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,2023–2030 (USD BILLION)
TABLE 34 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 35 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 36 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 37 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 38 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 39 MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,BY REGION, 2023–2030 (USD BILLION)
TABLE 40 GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 41 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION,2023–2030(USD BILLION)
TABLE 42 NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 43 EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 44 ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 45 LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 46 MIDDLE EAST: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,BY REGION, 2023–2030(USD BILLION)
TABLE 47 GCC COUNTRIES: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 48 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE,2023–2030(USD BILLION)
TABLE 49 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION,2023–2030(USD BILLION)
TABLE 50 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 51 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 52 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 53 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 54 MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY REGION, 2023–2030(USD BILLION)
TABLE 55 GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 56 PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 57 NORTH AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 58 EUROPE: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 59 ASIA PACIFIC: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 60 LATIN AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 61 MIDDLE EAST: PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
TABLE 62 GCC COUNTRIES: PARENTERAL MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 63 TABLET MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 64 NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 65 EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 66 ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 67 LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 68 MIDDLE EAST: TABLET MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 69 GCC COUNTRIES: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 70 CAPSULE MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 71 NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 72 EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 73 ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 74 LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 75 MIDDLE EAST: CAPSULE MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 76 GCC COUNTRIES: CAPSULE MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 77 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 78 NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 79 EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 80 ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 81 LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 82 MIDDLE EAST: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
TABLE 83 GCC COUNTRIES: ORAL LIQUID MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 84 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 85 NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 86 EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 87 ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 88 LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 89 MIDDLE EAST: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
TABLE 90 GCC COUNTRIES: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 91 OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 92 NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 93 EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 94 ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 95 LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 96 MIDDLE EAST: OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
TABLE 97 GCC COUNTRIES: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 98 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 99 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 100 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 101 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 102 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 103 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 104 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 105 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 106 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 107 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 108 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 109 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 110 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 111 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 112 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 113 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 114 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 115 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 116 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 117 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 118 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY REGION,2023–2030 (USD BILLION)
TABLE 119 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 120 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 121 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 122 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 123 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 124 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 125 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION,2023–2030 (USD BILLION)
TABLE 126 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 127 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 128 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 129 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 130 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 131 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 132 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 133 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 134 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 135 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 136 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 137 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 138 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 139 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL- FINISH SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 140 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 141 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 142 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 143 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 144 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 145 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 146 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 147 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 148 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE,2023–2030 (USD BILLION)
TABLE 149 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 150 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 151 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 152 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 153 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 154 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 155 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 156 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 157 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 158 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 159 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 160 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 161 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 162 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 163 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 164 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY REGION,2023–2030 (USD BILLION)
TABLE 165 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 166 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 167 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 168 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 169 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY REGION, 2023–2030 (USD BILLION)
TABLE 170 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 171 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 172 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 173 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 174 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 175 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 176 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 177 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 178 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 179 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 180 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 181 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 182 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 183 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 184 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 185 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 186 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 187 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 188 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 189 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 190 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 191 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 192 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 193 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 194 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 195 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 196 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 197 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 198 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 199 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 200 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 201 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 202 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 203 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 204 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 205 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 206 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 207 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY REGION, 2023–2030 (USD BILLION)
TABLE 208 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 209 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 210 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 211 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 212 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY REGION, 2023–2030 (USD BILLION)
TABLE 213 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 214 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES,BY REGION, 2023–2030 (USD BILLION)
TABLE 215 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 216 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 217 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 218 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 219 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD BILLION)
TABLE 220 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 221 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD BILLION)
TABLE 222 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 223 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 224 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 225 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 226 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD BILLION)
TABLE 227 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 228 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 229 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 230 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 231 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 232 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 233 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 234 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 235 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER,2023–2030 (USD BILLION)
TABLE 236 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 237 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 238 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 239 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 240 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 241 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 242 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 243 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 244 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 245 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 246 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 247 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 248 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION,2023–2030 (USD BILLION)
TABLE 249 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 250 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 251 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 252 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 253 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 254 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 255 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 256 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 257 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD BILLION)
TABLE 258 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 259 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 260 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 261 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 262 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD BILLION)
TABLE 263 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 264 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 265 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 266 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 267 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET,BY SERVICE, 2023–2030 (USD BILLION)
TABLE 268 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,BY TYPE, 2023–2030 (USD BILLION)
TABLE 269 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY TYPE, 2023–2030 (USD BILLION)
TABLE 270 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 271 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET,BY MOLECULE, 2023–2030 (USD BILLION)
TABLE 272 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 273 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 274 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET,BY END USER, 2023–2030 (USD BILLION)
TABLE 275 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE,2023–2030 (USD BILLION)
TABLE 276 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,2023–2030 (USD BILLION)
TABLE 277 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE,2023–2030 (USD BILLION)
TABLE 278 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 279 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET,BY MOLECULE, 2023–2030 (USD BILLION)
TABLE 280 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 281 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 282 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET,BY END USER, 2023–2030 (USD BILLION)
TABLE 1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RISK ANALYSIS
TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 5 GLP-1 PIPELINE, EXPECTED LAUNCH BY 2030
TABLE 6 ADC PIPELINE, EXPECTED LAUNCH BY 2030
TABLE 7 IMPENDING AND ONGOING PATENT EXPIRIES OF BLOCKBUSTER BIOLOGICS, 2023–2035
TABLE 8 LIST OF RECENTLY APPROVED INJECTABLES, 2022–2024
TABLE 9 CELL & GENE THERAPY-SPECIFIC CDMO EXPANSIONS, 2023–2025
TABLE 10 CELL & GENE THERAPY PIPELINE, EXPECTED LAUNCH BY 2030
TABLE 11 INDICATIVE PRICING ANALYSIS, BY SERVICE
TABLE 12 INDICATIVE PRICING ANALYSIS, BY REGION
TABLE 13 PRICING MODELS FOR CDMO SERVICES
TABLE 14 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN SUPPLY CHAIN
TABLE 15 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 16 MANUFACTURING SITES OF KEY CDMOS
TABLE 17 LIST OF SITE EXPANSIONS FOR KEY CDMOS, 2023–2025
TABLE 18 CAPEX FOR SELECTED PUBLICLY LISTED KEY CDMOS, 2021–2024 (USD MILLION)
TABLE 19 NUMBER OF PATENTS FILED IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, 2014–2024
TABLE 20 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
TABLE 21 REGULATORY SCENARIO, BY COUNTRY
TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 27 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 28 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PHARMACEUTICAL CONTRACT MANUFACTURING SERVICES (%)
TABLE 30 BUYING CRITERIA FOR PHARMACEUTICAL CONTRACT MANUFACTURING,BY END USER
TABLE 31 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 32 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE,2023–2030 (USD BILLION)
TABLE 33 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,2023–2030 (USD BILLION)
TABLE 34 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 35 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 36 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 37 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 38 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 39 MIDDLE EAST: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,BY REGION, 2023–2030 (USD BILLION)
TABLE 40 GCC COUNTRIES: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 41 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION,2023–2030(USD BILLION)
TABLE 42 NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 43 EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 44 ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 45 LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 46 MIDDLE EAST: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,BY REGION, 2023–2030(USD BILLION)
TABLE 47 GCC COUNTRIES: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 48 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE,2023–2030(USD BILLION)
TABLE 49 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION,2023–2030(USD BILLION)
TABLE 50 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 51 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 52 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 53 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 54 MIDDLE EAST: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY REGION, 2023–2030(USD BILLION)
TABLE 55 GCC COUNTRIES: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030(USD BILLION)
TABLE 56 PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 57 NORTH AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 58 EUROPE: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 59 ASIA PACIFIC: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 60 LATIN AMERICA: PARENTERAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 61 MIDDLE EAST: PARENTERAL MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
TABLE 62 GCC COUNTRIES: PARENTERAL MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 63 TABLET MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 64 NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 65 EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 66 ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 67 LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 68 MIDDLE EAST: TABLET MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 69 GCC COUNTRIES: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 70 CAPSULE MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 71 NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 72 EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 73 ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 74 LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 75 MIDDLE EAST: CAPSULE MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 76 GCC COUNTRIES: CAPSULE MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 77 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 78 NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 79 EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 80 ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 81 LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 82 MIDDLE EAST: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
TABLE 83 GCC COUNTRIES: ORAL LIQUID MANUFACTURING SERVICES MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 84 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 85 NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 86 EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 87 ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 88 LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 89 MIDDLE EAST: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
TABLE 90 GCC COUNTRIES: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 91 OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 92 NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 93 EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 94 ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 95 LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 96 MIDDLE EAST: OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2023–2030 (USD BILLION)
TABLE 97 GCC COUNTRIES: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 98 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 99 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 100 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 101 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 102 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 103 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 104 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR DRUG DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 105 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 106 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 107 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 108 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 109 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 110 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 111 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 112 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 113 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 114 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 115 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 116 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 117 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 118 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY REGION,2023–2030 (USD BILLION)
TABLE 119 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS API MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 120 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 121 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 122 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 123 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 124 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 125 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION,2023–2030 (USD BILLION)
TABLE 126 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS FDF MANUFACTURING SERVICES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 127 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 128 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 129 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 130 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 131 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 132 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 133 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR PACKAGING & LABELING SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 134 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 135 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 136 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 137 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 138 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 139 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL- FINISH SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 140 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR FILL-FINISH SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 141 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 142 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 143 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 144 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 145 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 146 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY REGION, 2023–2030 (USD BILLION)
TABLE 147 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SERVICES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 148 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE,2023–2030 (USD BILLION)
TABLE 149 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 150 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 151 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 152 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 153 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 154 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 155 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 156 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 157 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 158 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 159 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 160 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 161 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 162 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH-POTENCY SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 163 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR HIGH POTENCY SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 164 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY REGION,2023–2030 (USD BILLION)
TABLE 165 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 166 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 167 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 168 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 169 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY REGION, 2023–2030 (USD BILLION)
TABLE 170 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OLIGONUCLEOTIDES AND SYNTHETIC PEPTIDES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 171 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 172 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 173 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 174 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 175 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 176 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 177 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR RADIOPHARMACEUTICAL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 178 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 179 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 180 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 181 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 182 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 183 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 184 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 185 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 186 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 187 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 188 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 189 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 190 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 191 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 192 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 193 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 194 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 195 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 196 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 197 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 198 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 199 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 200 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 201 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 202 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 203 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 204 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 205 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 206 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 207 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY REGION, 2023–2030 (USD BILLION)
TABLE 208 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 209 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 210 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 211 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 212 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY REGION, 2023–2030 (USD BILLION)
TABLE 213 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 214 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES,BY REGION, 2023–2030 (USD BILLION)
TABLE 215 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 216 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 217 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 218 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 219 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2023–2030 (USD BILLION)
TABLE 220 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 221 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD BILLION)
TABLE 222 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 223 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 224 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 225 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 226 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2023–2030 (USD BILLION)
TABLE 227 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 228 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 229 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 230 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 231 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 232 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 233 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY REGION, 2023–2030 (USD BILLION)
TABLE 234 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER LARGE MOLECULES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 235 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER,2023–2030 (USD BILLION)
TABLE 236 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 237 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 238 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 239 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 240 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 241 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 242 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 243 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 244 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 245 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 246 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 247 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 248 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION,2023–2030 (USD BILLION)
TABLE 249 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 250 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 251 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 252 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 253 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 254 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 255 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD BILLION)
TABLE 256 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY,2023–2030 (USD BILLION)
TABLE 257 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD BILLION)
TABLE 258 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 259 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 260 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 261 LATIN AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 262 MIDDLE EAST: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD BILLION)
TABLE 263 GCC COUNTRIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 264 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION,2023–2030 (USD BILLION)
TABLE 265 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
TABLE 266 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET,BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 267 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET,BY SERVICE, 2023–2030 (USD BILLION)
TABLE 268 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,BY TYPE, 2023–2030 (USD BILLION)
TABLE 269 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,BY TYPE, 2023–2030 (USD BILLION)
TABLE 270 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 271 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET,BY MOLECULE, 2023–2030 (USD BILLION)
TABLE 272 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 273 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 274 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET,BY END USER, 2023–2030 (USD BILLION)
TABLE 275 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE,2023–2030 (USD BILLION)
TABLE 276 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,2023–2030 (USD BILLION)
TABLE 277 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE,2023–2030 (USD BILLION)
TABLE 278 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR BIOLOGICS MANUFACTURING SERVICES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 279 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET,BY MOLECULE, 2023–2030 (USD BILLION)
TABLE 280 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 281 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 282 US: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET,BY END USER, 2023–2030 (USD BILLION)
LIST OF FIGURES
FIGURE 1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION AND REGIONAL SCOPE
FIGURE 2 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: YEARS CONSIDERED
FIGURE 3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RESEARCH DESIGN
FIGURE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY DATA FROM SECONDARY SOURCES
FIGURE 5 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2024
FIGURE 8 REVENUE SHARE ANALYSIS OF THERMO FISHER SCIENTIFIC INC., 2024
FIGURE 9 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 10 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: TOP-DOWN APPROACH
FIGURE 11 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS
FIGURE 12 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DATA TRIANGULATION
FIGURE 13 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2025 VS. 2030 (USD BILLION)
FIGURE 14 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD BILLION)
FIGURE 15 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2025 VS. 2030 (USD BILLION)
FIGURE 16 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
FIGURE 17 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2025–2030
FIGURE 18 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET
FIGURE 19 PHARMACEUTICAL MANUFACTURING SERVICES AND US TO LEAD NORTH AMERICAN MARKET IN 2025
FIGURE 20 SMALL MOLECULES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 21 BIG PHARMACEUTICAL COMPANIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 22 CHINA TO HAVE LARGEST MARKET DURING FORECAST PERIOD
FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
FIGURE 24 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 25 NEW REVENUE POCKETS FOR PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FIGURE 26 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: VALUE CHAIN ANALYSIS
FIGURE 27 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 28 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ECOSYSTEM ANALYSIS
FIGURE 29 INVESTMENT AND FUNDING SCENARIO, 2023–2024
FIGURE 30 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024
FIGURE 31 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY SERVICE
FIGURE 33 KEY BUYING CRITERIA FOR END USERS
FIGURE 34 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS, 2020–2025
FIGURE 35 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: AI USE CASES
FIGURE 36 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
FIGURE 37 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
FIGURE 39 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
FIGURE 40 EV/EBITDA OF KEY VENDORS
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 42 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BRAND/SERVICE COMPARISON
FIGURE 43 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 44 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY FOOTPRINT
FIGURE 45 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
FIGURE 47 LONZA: COMPANY SNAPSHOT (2024)
FIGURE 48 CATALENT, INC.: COMPANY SNAPSHOT (2023)
FIGURE 49 WUXI APPTEC: COMPANY SNAPSHOT (2024)
FIGURE 50 WUXI BIOLOGICS: COMPANY SNAPSHOT (2024)
FIGURE 51 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2024)
FIGURE 52 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024)
FIGURE 53 EVONIK: COMPANY SNAPSHOT (2024)
FIGURE 54 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 55 ABBVIE INC.: COMPANY SNAPSHOT (2024)
FIGURE 56 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2024)
FIGURE 57 MERCK KGAA: COMPANY SNAPSHOT (2024)
FIGURE 58 ALMAC GROUP: COMPANY SNAPSHOT (2024)
FIGURE 59 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)
FIGURE 60 ASYMCHEM INC.: COMPANY SNAPSHOT (2024)
FIGURE 61 VETTER: COMPANY SNAPSHOT (2024)
FIGURE 62 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
FIGURE 1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SEGMENTATION AND REGIONAL SCOPE
FIGURE 2 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: YEARS CONSIDERED
FIGURE 3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RESEARCH DESIGN
FIGURE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: KEY DATA FROM SECONDARY SOURCES
FIGURE 5 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2024
FIGURE 8 REVENUE SHARE ANALYSIS OF THERMO FISHER SCIENTIFIC INC., 2024
FIGURE 9 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 10 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: TOP-DOWN APPROACH
FIGURE 11 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS
FIGURE 12 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DATA TRIANGULATION
FIGURE 13 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2025 VS. 2030 (USD BILLION)
FIGURE 14 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD BILLION)
FIGURE 15 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2025 VS. 2030 (USD BILLION)
FIGURE 16 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
FIGURE 17 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION, 2025–2030
FIGURE 18 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET
FIGURE 19 PHARMACEUTICAL MANUFACTURING SERVICES AND US TO LEAD NORTH AMERICAN MARKET IN 2025
FIGURE 20 SMALL MOLECULES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 21 BIG PHARMACEUTICAL COMPANIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
FIGURE 22 CHINA TO HAVE LARGEST MARKET DURING FORECAST PERIOD
FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
FIGURE 24 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 25 NEW REVENUE POCKETS FOR PLAYERS IN PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
FIGURE 26 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: VALUE CHAIN ANALYSIS
FIGURE 27 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 28 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ECOSYSTEM ANALYSIS
FIGURE 29 INVESTMENT AND FUNDING SCENARIO, 2023–2024
FIGURE 30 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024
FIGURE 31 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY SERVICE
FIGURE 33 KEY BUYING CRITERIA FOR END USERS
FIGURE 34 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS, 2020–2025
FIGURE 35 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: AI USE CASES
FIGURE 36 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
FIGURE 37 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
FIGURE 39 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
FIGURE 40 EV/EBITDA OF KEY VENDORS
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 42 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: BRAND/SERVICE COMPARISON
FIGURE 43 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 44 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY FOOTPRINT
FIGURE 45 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
FIGURE 47 LONZA: COMPANY SNAPSHOT (2024)
FIGURE 48 CATALENT, INC.: COMPANY SNAPSHOT (2023)
FIGURE 49 WUXI APPTEC: COMPANY SNAPSHOT (2024)
FIGURE 50 WUXI BIOLOGICS: COMPANY SNAPSHOT (2024)
FIGURE 51 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2024)
FIGURE 52 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024)
FIGURE 53 EVONIK: COMPANY SNAPSHOT (2024)
FIGURE 54 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 55 ABBVIE INC.: COMPANY SNAPSHOT (2024)
FIGURE 56 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2024)
FIGURE 57 MERCK KGAA: COMPANY SNAPSHOT (2024)
FIGURE 58 ALMAC GROUP: COMPANY SNAPSHOT (2024)
FIGURE 59 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)
FIGURE 60 ASYMCHEM INC.: COMPANY SNAPSHOT (2024)
FIGURE 61 VETTER: COMPANY SNAPSHOT (2024)
FIGURE 62 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)
